Login
$ERNA
$1.65 -$0.03 (1.79%) Live

$ERNA 8-K/A SEC Filings

Filed On Filing
26 Sep 2023 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

01 Sep 2022 8-K/A: Departure/Election of Directors or Officers; Compensation

The purpose of this separation agreement (the “Separation Agreement”) is to memorialize the terms and conditions of the separation of your employment with Brooklyn ImmunoTherapeutics, Inc. (the “Company”) and its subsidiaries and affilia...

01 Oct 2021 8-K/A: Financial Statements and Exhibits

We have determined that the historical financial statements of Novellus are not required to be filed as the acquisition of Novellus was not a “significant” transaction as defined in Regulation S-X.

30 Apr 2021 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined financial statements give effect to the merger of BIT Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of NTN Buzztime, Inc. (“NTN”), with and into Brooklyn ImmunoTherapeutic...

14 Mar 2016 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This first AMENDMENT TO Loan and security agreement AND WAIVER (this “Amendment”), dated as of March 10, 2016, is entered into by and between EAST WEST BANK, a California banking corporation (“Bank”), and NTN BUZZTIME, INC., a Delaware c...

13 Jun 2013 8-K/A: Submission of Matters to a Vote of Security Holders

At the 2013 annual meeting of stockholders held on June 7, 2013, the Company’s stockholders considered and voted upon the following proposals:

15 Jun 2006 8-K/A: Financial Statements and Exhibits
14 Oct 2003 8-K/A: Financial Statements and Exhibits

We consent to incorporation by reference in the registration statements (No. 333-60814. No. 333-17247, No. 333-12777 and No. 33-95776) on Form S-8 and in the registration statements (No. 333-105429, No. 333-80143, No. 333-69383, No. 333-...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support